1. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ & Bursell SE (2006) Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Investigative Ophthalmology and Visual Science 47 86–92.
2. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Björkhem I, Pettersson S, Gustafsson JA (March 2001). "Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRß-deficient mice". J. Clin. Invest. 107 (5): 565–73.
3. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M (October 1994). "A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily". Mol. Cell. Biol. 14(10): 7025–35.
4. Bensinger, S.J. et al. (2008) LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134, 97–111.
5. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature; 455:1061–8.
6. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, et al. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol.; 22:1926–33.
7. Charlton-Menys V, Durrington PN (2008) Human cholesterol metabolism and therapeutic molecules. Exp Physiol 93: 27–42.
8. Christopher J Delvecchio and John P Capone (2008) Examining the Relationship between Cholesterol and Cancer Does HDL-C Have a Protective Role? By Genna Rollins (Clinical Laboratory Strategies).
9. Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY and Liao S (2006) Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res; 66: 6482- 6.
10. Chuu CP, Kokontis JM, Hiipakka RA, Liao S (2007). "Modulation of liver X receptor signaling as novel therapy for prostate cancer". J. Biomed. Sci. 14 (5): 543–53.
11. Chuu, C.P. (2011) Modulation of liver X receptor signaling as a prevention and therapy for colon cancer. Med. Hypothese 76, 697–699
12. Collins JL (2004) Therapeutic opportunities for liver X receptor modulators. Current Opinion in Drug Discovery and Development 7 692–702.
13. Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD, Morgan DG, Beaudet EJ, Whitney KD, Kliewer SA &Willson TM (2002) Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem, Vol.45, No.10, pp.1963-1966.
14. Connell-Crowley L, Harper JW, Goodrich DW (1997) Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell, 8:287-301.
15. Demetrius Albanes, M.D. Senior Investigator National Cancer Institute Division of Cancer Epidemiology & Genetics, Nutritional Epidemiology Branch Mumbai.
16. De Stefani, E. et al. (2000) Plant sterols and risk of stomach cancer: a case–control study in Uruguay. Nutr. Cancer 37, 140–144.
17. Dey D, Basu D, Roy SS, Bandyopadhyay A & Bhattacharya S (2006) Involvement of novel PKC isoforms in FFA induced defects in insulin signaling. Molecular and Cellular Endocrinology 246 60–64.
18. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG (2002) Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer, 94:2766-92.
19. Forman BM, Ruan B, Chen J, Schroepfer GJ, Jr. &Evans RM (1997) The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci U S A, Vol.94, No.20, pp.10588-10593.
20. Fukuchi, J. et al. (2004) Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 64, 7686–7689.
21. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.; 21:2683–710.
22. Geyeregger, R., Shehata, M., Zeyda, M., Kiefer, F., Stuhlmeier, K., Porpaczy, E., Zlabinger, G., Jager, U., Stulnig, T. (2009) Liver X receptors interfere with cytokine-induced proliferation and cell survival in nor- mal and leukemic lymphocytes. J. Leukoc. Biol.86, 1039–1048.
23. Guo, D. et al. (2011) An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 1, 442–456
24. Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reijngoud DJ & Kuipers F (2005) Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. American Journal of Physiology. Endocrinology and Metabolism, 289 E829–E838.
25. Haibiao Gong, Ping Guo, Yonggong Zhai, Jie Zhou, Hirdesh Uppal, Michael J. Jarzynka, Wen-Chao Song, Shi-Yuan Cheng, and Wen Xie (2007), Estrogen Deprivation and Inhibition of BreastbCancer Growth in Vivo through Activation of the Orphan Nuclear Receptor Liver X Receptor: Molecular Endocrinology 21(8):1781–1790.
26. Holland EC (2001) Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet.; 2:120–9.
27. Im SS, Osborne TF (April 2011). "Liver x receptors in atherosclerosis and inflammation". Circulation Research 108 (8): 996-1001.
28. Jemal A, Siegel T, Ward E, Hao Y, Murray T, Thun MJ (2008) Cancer statistics. CA Cancer J Clin , 55:10-30.
29. James J Rough, M Alexandra Monroy, Smitha Yerrum and John M Daly (2010), Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells, Rough et al. Journal of Ovarian Research, 3:13.
30. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011). Global cancer statistics. CA Cancer J Clin; 61: 69-90.
31. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P (May 2002). "Synthetic LXR ligand inhibits the development of atherosclerosis in mice". Proc. Natl. Acad. Sci. U.S.A. 99 (11): 7604–9.
32. Kaneko E, Matsuda M, Yamada Y, Tachibana Y, Shimomura I &Makishima M (2003) Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem, Vol.278, No.38, (Sep 2003), pp.36091-36098.
33. Kent W. Christopherson and Alan Landay (2009) Liver X receptor a(LXRa) as atherapeutic target in chronic lymphocytic leukemia (CLL), Journal of Leukocyte Biology Volume 86, November.
34. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG &Lazo JS (2005) The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem, Vol.280, No.6, pp.4079-4088.
35. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D (February 2009). "Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia" J. Lipid Res. 50 (2): 312–26.
36. Krycer JR and Brown AJ (2011) Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis. J Biol Chem ; 286: 20637-47.
37. Lee JH, Gong H, Khadem S, Lu Y, Gao X, Li S, Zhang J and Xie W. Androgen deprivation by activating the liver X receptor. Endocrinology 2008; 149: 3778-88.
38. Lo Sasso, G. et al. (2010) Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. Hepatology 51, 1334–1344.
39. Makishima S (2006) Nuclear receptors sense bile acid metabolism: a hormonal action of bile acids. In Functional and Structural Biology on the Lipo-Network, pp 17–35. Eds K Morikawa & S Tate. Kerala: Transworld Research Network.
40. McCann, S.E. et al. (2005) Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr. Cancer 53, 33–41.
41. Mendilaharsu, M. et al. (1998) Phytosterols and risk of lung cancer: a case–control study in Uruguay. Lung Cancer 21, 37–45.
42. Ronco, A. et al. (1999) Vegetables, fruits, and related nutrients and risk of breast cancer: a case–control study in Uruguay. Nutr. Cancer 35, 111–119.
43. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science; 321:1807–12.
44. Plat, J. et al. (2005) Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J. Lipid Res. 46, 2468–2476.
45. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD &Shan B (2000) Role of LXRs in control of lipogenesis.Genes Dev, Vol.14, No.22, (Nov 2000), pp.2831-2838.
46. Song C &Liao S (2001) Hypolipidemic effects of selective liver X receptor alpha agonists.Steroids, Vol.66, No.9, pp.673-681.
47. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 13:1501-12.
48. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA,McLeod DG, Moul JW, Vahey M and Srivastava S (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene; 21: 8749-58.
49. Song WC (2001) Biochemistry and reproductive endocrinology of estrogen sulfotransferase. Ann NY Acad Sci 948:43–50.
50. Song WC, Qian Y, Li AP (1998) Estrogen sulfotransferase expression in the human liver: marked interindividual variation and lack of gender specificity. J Pharmacol Exp. Ther 284:1197–1202.
51. Song C, Hiipakka RA, Liao S (June 2001). "Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis". Steroids 66 (6): 473–9.
52. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med.; 352:987–96.
53. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010; 20:87–90.
54. Wirfalt, E. et al. (2009) Associations between food patterns defined by cluster analysis and colorectal cancer incidence in the NIH-AARP diet and health study. Eur. J. Clin. Nutr. 63, 707–717.
55. Willy, P. J. et al. (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9, 1033–1045.
56. Villablanca, E.J. et al. (2010) Tumor-mediated liver X receptor-a activation inhibits CC chemokine receptor-7 expression on Dendritic cells and dampens antitumor responses. Nat. Med. 16, 98–105.
57. Viennois, E. et al. (2012) Selective liver X receptor modulators (SLiMs): what use in human health? Mol. Cell. Endocrinol. 351, 129–14.
58. Zumsteg ZS and Zelefsky MJ (2012) Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol; 13: e259-269.